Ralph Eugene, APRN
Psychiatric/Mental Health · North Providence, RINPI 1225435829
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,522 of the $2,401 with a category attached, or 63.4%. 8 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 39.6% of the total.
Across 30 payments — averaging $80.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$950
- Teva Pharmaceuticals USA, Inc.$702
- Otsuka America Pharmaceutical, Inc.$341
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$204
- Alkermes, Inc.$102
- AbbVie$51
- plus $50 from 2 others
What the payments were for
- Consulting fees$83335%
- Food & beverage$1,52263%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 5 | $950 |
| Teva Pharmaceuticals USA, Inc. | 11 | $702 |
| Otsuka America Pharmaceutical, Inc. | 4 | $341 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $204 |
| Alkermes, Inc. | 1 | $102 |
| AbbVie | 2 | $51 |
| Lundbeck LLC | 2 | $31 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$410
- UZEDY$233
- Austedo XR$231
- CAPLYTA$130
- REXULTI$121
- ABILIFY ASIMTUFII$120
- ABILIFY MAINTENA$120
How this compares
$2,401 in reported general payments places this provider in the 80th percentile of 196 psychiatric/mental health providers in Rhode Island.
See all psychiatric/mental health providers in Rhode Island →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 14 | $257 |
| Trazodone Hcl | 12 | $58 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in North Providence
- Nancy SerabianNorth Providence$8K
- Catherine Trim-DeignanNorth Providence$1K
- Samantha Shawn MarshBradford$639K
- Samuel KaufmanRiverside$19K
- Katie ThayerWarwick$16K
- Arielle RoundsWarwick$15K
- Eniayo EgberongbeCranston$12K
- Deborah HorvitzWarwick$10K
- Donna McDonaldProvidence$9K
- Timothy PepinNorth Smithfield$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.